American Association for Cancer Research
Browse
00085472can193247-sup-230823_3_supp_6342557_qbkmbx.docx (238.54 kB)

Figure S6 from Oxygen-Enhanced Optoacoustic Tomography Reveals the Effectiveness of Targeting Heme and Oxidative Phosphorylation at Normalizing Tumor Vascular Oxygenation

Download (238.54 kB)
journal contribution
posted on 2023-03-31, 03:24 authored by Poorva Ghosh, Yihang Guo, Adnin Ashrafi, Jingyu Chen, Sanchareeka Dey, Shigen Zhong, Jie Liu, James Campbell, Purna Chaitanya Konduri, Jeni Gerberich, Massoud Garrossian, Ralph P. Mason, Li Zhang, Li Liu

Fig. S6 Analysis of correlation between tumor sizes and MSOT metrics. (A, B, & C) sO2 (Air), sO2 (O2), and Î"sO2 as derived from MSOT data. No significant correlation was detected between any MSOT metric with tumor sizes measured ex vivo. (D) Summary of p-values and r correlations of MSOT and OE-MSOT metrics with tumor sizes. For statistical analysis, the levels in treated tumors were compared to the levels in control tumors with a Welch 2-sample t-test or Pearson r correlation.

Funding

Cancer Prevention and Research Institute of Texas grants

NIH

CPRIT

History

ARTICLE ABSTRACT

Multispectral optoacoustic tomography (MSOT) is an emerging noninvasive imaging modality that can detect real-time dynamic information about the tumor microenvironment in humans and animals. Oxygen enhanced (OE)-MSOT can monitor tumor vasculature and oxygenation during disease development or therapy. Here, we used MSOT and OE-MSOT to examine in mice the response of human non–small cell lung cancer (NSCLC) xenografts to a new class of antitumor drugs, heme-targeting agents heme-sequestering peptide 2 (HSP2) and cyclopamine tartrate (CycT). HSP2 inhibits heme uptake, while CycT inhibits heme synthesis in NSCLC cells, where heme is essential for ATP generation via oxidative phosphorylation. HSP2 and CycT can inhibit ATP generation and thereby suppress NSCLC cell tumorigenic functions. MSOT showed that treatment of NSCLC tumors with HSP2 or CycT reduced total hemoglobin, increased oxygen saturation, and enhanced the amplitude of response to oxygen gas breathing challenge. HSP2 and CycT normalized tumor vasculature and improved tumor oxygenation, where levels of several hypoxia markers in NSCLC tumors were reduced by treatment with HSP2 or CycT. Furthermore, treatment with HSP2 or CycT reduced levels of angiogenic factor VEGFA, its receptor VEGFR1, and vascular marker CD34. Together, our data show that heme-targeting drugs HSP2 and CycT elicit multiple tumor-suppressing functions, such as inhibiting angiogenic function, normalizing tumor vasculature, alleviating tumor hypoxia, and inhibiting oxygen consumption and ATP generation. Heme-targeting agents HSP2 and CycT effectively normalize tumor vasculature and alleviate tumor hypoxia, raising the possibility of their combination with chemo-, radio-, and immunotherapies to improve antitumor efficacy.See related commentary by Tomaszewski, p. 3461

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC